<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00799721</url>
  </required_header>
  <id_info>
    <org_study_id>EA2/072/08-1</org_study_id>
    <nct_id>NCT00799721</nct_id>
  </id_info>
  <brief_title>Urine VEGF Levels in Very Low Birth Weight (VLBW) Infants</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <brief_summary>
    <textblock>
      VLBW infants are at risk of developing retinopathy of prematurity (ROP). In the first phase
      of ROP there is a down-regulation of retinal VEGF-expression because of postnatal relative
      hyperoxia, followed by an upregulation of VEGF mediated through retinal hypoxia, which leads
      to pathologic vessel formation. VEGF acts through binding to the specific receptor FLT-1, the
      soluble form sFLT-1 is a specific antagonist of VEGF action. Erythropoietin, given to VLBW
      infants to prevent anemia, may stimulate VEGF-production in neuronal cells. Currently, there
      are no data published about VEGF urine-levels in VLBW infants and it is not known, if urine
      VEGF-levels may serve as a non-invasive marker of ROP-risk. Further shall be investigated, if
      erythropoietin-therapy increases urine VEGF-levels and if there is a correlation with
      ROP-development.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2008</start_date>
  <completion_date type="Anticipated">December 2010</completion_date>
  <primary_completion_date type="Anticipated">February 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Development of ROP</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Infant, Very Low Birth Weight</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>VLBW infants with erythropoietin therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>VLBW infants without erythropoietin therapy.</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Urine samples that are centrifugated to get rid of any cells where stored at -80°C until
      ELISA is done.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Pretarem infants of less than 32 weeks of gestation or birth weight below 1500g.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  gestational age &lt; 32 weeks

          -  birth weight &lt;1500g

        Exclusion Criteria:

          -  absent written consent by parents

          -  connatal eye malformation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>32 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Anke Reinhold, Doctor</last_name>
    <phone>+49/177/2950661</phone>
    <email>anke.reinhold@charite.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anja Pohl-Schickinger, Doctor</last_name>
    <phone>+49/30/450566122</phone>
    <email>anja.pohl@charite.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Charité Virchow-Hospital</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anke Reinhold, Doctor</last_name>
      <email>anke.reinhold@charite.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 28, 2008</study_first_submitted>
  <study_first_submitted_qc>November 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2008</study_first_posted>
  <last_update_submitted>November 28, 2008</last_update_submitted>
  <last_update_submitted_qc>November 28, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 1, 2008</last_update_posted>
  <responsible_party>
    <name_title>Dr. Anke Reinhold</name_title>
    <organization>Charité University Berlin</organization>
  </responsible_party>
  <keyword>ROP</keyword>
  <keyword>VLBW</keyword>
  <keyword>Epo</keyword>
  <keyword>IUGR</keyword>
  <keyword>VEGF</keyword>
  <keyword>sFLT-1</keyword>
  <keyword>very low birth weight infants</keyword>
  <keyword>retinopathy of prematurity</keyword>
  <keyword>erythropoietin therapy and risk of ROP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Birth Weight</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

